Developer docs
API playgroundTry for free, no card

Search company profiles

Opus Genetics(formerly Ocuphire Pharma)

Full company profile

uuid000365d

Namestring
Opus Genetics(formerly Ocuphire Pharma)
Legal namestring
Opus Genetics, Inc.
Websiteurl
opusgtx.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Opus Genetics, Inc. (NASDAQ: IRD; formerly Ocuphire Pharma) is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina, that develops AAV-based gene therapies for inherited retinal diseases (IRDs) and small-molecule ophthalmic therapeutics for refractive disorders and diabetic retinopathy. The company's core technology platform delivers functional genes via adeno-associated virus vectors to retinal photoreceptors or retinal pigment epithelial cells, with a pipeline of seven programs targeting LCA5, BEST1, RDH12, MERTK, RHO, CNGB1, and NMNAT1 mutations. Its lead gene therapy asset OPGx-LCA5 is in Phase 1/2 development for Leber congenital amaurosis, and OPGx-BEST1 is advancing toward the clinic for bestrophin-1-related retinal degeneration.

The company operates a hybrid business model. Nyxol (phentolamine ophthalmic solution 0.75%, branded RYZUMVI for mydriasis reversal) was FDA-approved in September 2023 and is commercialized globally by Viatris under a licensing agreement with FamyGen Life Sciences; Opus receives milestone payments and tiered double-digit royalties on worldwide net sales through 2040. APX3330, an oral Ref-1 inhibitor for diabetic retinopathy, was developed internally. The gene therapy programs are funded through a combination of dilutive equity (e.g., the $25M February 2026 Series B preferred led by Adage Capital Management) and non-dilutive strategic capital (up to $155M from Oberland Capital in April 2026, extending runway into 2029).

Opus is backed by the Foundation Fighting Blindness's RD Fund and has access to its 40-site Clinical Research Consortium and the Uni-Rare natural history study covering ~1,500 patients across over 300 IRD-associated genes. The company was formed through the November 2020 reverse merger of Ocuphire Pharma with Rexahn Pharmaceuticals, rebranded as Opus Genetics in 2023 following its strategic pivot toward AAV gene therapy, and is led by CEO George Magrath (appointed November 2023).

Short descriptiontext

Opus Genetics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases and small-molecule ophthalmic drugs, with seven gene therapy programs led by OPGx-LCA5 and partnered commercialization of approved RYZUMVI via Viatris.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFarmington Hills, United States
HQ citystring
Farmington Hills
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic gene therapy, inherited retinal diseases, AAV gene therapy, retinal biopharmaceuticals, ophthalmic pharmaceuticals
Industry4 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties and Milestone Payments
TypeLicensing Royalties
Description

Under the global license agreement with FamyGen/Viatris for Nyxol, Ocuphire receives upfront payments, development funding, regulatory milestone payments upon FDA approvals, tiered double-digit royalties on worldwide net sales through 2040, and sales milestone payments upon achievement of annual sales thresholds. Received $35 million upfront and eligible for $10 million upon RM approval.

ir.opusgtx.com
2Non-Dilutive Financing
TypeLicensing Royalties
Description

Strategic financing agreement with Oberland Capital providing up to $155 million in non-dilutive funding including $35 million upfront payment and $5 million equity investment, with potential additional funding tied to development milestones. This extends cash runway into 2029.

globenewswire.com
3Equity Financing
TypeOne Time License
Description

Private placement financing through sale of Series B Non-Voting Convertible Preferred Stock to institutional investors including Adage Capital Management, Trails Edge Capital Partners, and Marshall Wace, raising $25 million in gross proceeds.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1OPGx-LCA5
Description

AAV-based gene therapy program for LCA5-related mutations (Leber congenital amaurosis)

opusgtx.com
+6 more records
Core offering1 text field

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs), with seven pipeline programs targeting LCA5, BEST1, RDH12, MERTK, RHO, CNGB1, and NMNAT1 mutations. The company also advances Nyxol/RYZUMVI (phentolamine ophthalmic solution 0.75%) for mydriasis reversal, presbyopia, and night vision disturbances, plus APX3330, an oral Ref-1 inhibitor for diabetic retinopathy. Its lead programs OPGx-LCA5 and OPGx-BEST1 are advancing through clinical evaluation with FDA Rare Pediatric Disease Designation granted to OPGx-LCA5.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • OPGx-LCA5 received FDA Rare Pediatric Disease Designation, which may provide eligibility for a priority review voucher upon approval
+3 more records
Product overview1 text field

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs). The company's pipeline includes seven AAV-based gene therapy programs led by OPGx-LCA5 and OPGx-BEST1, with additional candidates targeting RDH12, MERTK, RHO, CNGB1, and NMNAT1. The company also continues to advance Nyxol/Phentolamine Ophthalmic Solution (marketed as RYZUMVI for reversal of mydriasis) and APX3330 (oral Ref-1 inhibitor for diabetic retinopathy) through its partnership with Viatris and FamyGen Life Sciences. Opus Genetics was formerly known as Ocuphire Pharma and operates from Research Triangle Park, NC.

Product and service10 records
1OPGx-LCA5
CategoryOphthalmic Gene Therapy
Description

AAV8-based gene therapy candidate designed to deliver a functional LCA5 gene to retinal photoreceptors for treatment of Leber congenital amaurosis (LCA) caused by LCA5 gene mutations. One of the lead programs in Opus Genetics' seven AAV-based gene therapy pipeline, with FDA Rare Pediatric Disease Designation granted.

2OPGx-BEST1
CategoryOphthalmic Gene Therapy
Description

Gene therapy candidate for BEST1-related inherited retinal degeneration, designed to deliver a functional BEST1 gene to retinal pigment epithelial cells to produce bestrophin-1 protein and normalize photoreceptor homeostasis. Acquired from Iveric Bio in December 2022.

3OPGx-RDH12
CategoryOphthalmic Gene Therapy
Description

Preclinical gene therapy program targeting RDH12 mutations for inherited retinal diseases. Part of the company's seven AAV-based gene therapy pipeline, with clinical entry expected in 2026.

4OPGx-MERTK
CategoryOphthalmic Gene Therapy
Description

Preclinical gene therapy program targeting MERTK mutations for inherited retinal diseases. Part of the company's seven AAV-based gene therapy pipeline, with clinical entry expected in 2026.

5OPGx-RHO
CategoryOphthalmic Gene Therapy
Description

Gene therapy candidate acquired from Iveric Bio for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), affecting approximately one in 51,000 people in the United States.

6OPGx-CNGB1
CategoryOphthalmic Gene Therapy
Description

Preclinical AAV-based gene therapy program in the company's pipeline for inherited retinal diseases, targeting CNGB1 mutations.

7OPGx-NMNAT1
CategoryOphthalmic Gene Therapy
Description

Preclinical AAV-based gene therapy program in the company's pipeline for inherited retinal diseases, targeting NMNAT1 mutations.

8RYZUMVI (Phentolamine Ophthalmic Solution 0.75%)
CategoryOphthalmic Pharmaceutical
Description

FDA-approved eye drop (Phentolamine Ophthalmic Solution 0.75%) for reversal of pharmacologically-induced mydriasis. Commercialized by partner Viatris following September 2023 FDA approval. Demonstrated statistically significant superiority vs placebo in returning dilated eyes to baseline pupil diameter as early as 60 and 90 minutes.

9Nyxol (Phentolamine Ophthalmic Solution 0.75%)
CategoryOphthalmic Pharmaceutical
Description

Preservative-free eye drop formulation of phentolamine mesylate 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. Developed for reversal of pharmacologically-induced mydriasis (RM), presbyopia, and dim light/night vision disturbances (NVD). Licensed to Viatris for global commercialization.

10APX3330
CategoryOphthalmic Pharmaceutical
Description

Oral small-molecule inhibitor of Ref-1 (reduction-oxidation effector factor-1) for treatment of diabetic retinopathy and diabetic macular edema. First-in-class drug candidate with dual mechanism of action reducing both angiogenesis (VEGF) and inflammation (NF-kB) pathways. ZETA-1 Phase 2 trial demonstrated 0% binocular 3-step worsening vs 16% for placebo (p=0.04).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-28
Description

Acquired rights to two preclinical-stage AAV-based gene therapy candidates for BEST1-related inherited retinal diseases and RHO-mediated autosomal dominant retinitis pigmentosa. Iveric received $500,000 upfront payment and high single-digit percentage ownership of Opus, with potential for development and regulatory milestone payments and low single-digit earnout on net sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-14
Description

Global, 40-site network of clinical research centers conducting the Uni-Rare natural history study for inherited retinal diseases. Jaeb Center for Health Research serves as coordinating center.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-07
Description

Global license agreement for commercialization of Nyxol across three indications (reversal of mydriasis, presbyopia, night vision disturbances) in US, Europe, Japan, India, China and other global markets. Viatris received rights following separate transaction with FamyGen Life Sciences.

4FamyGen Life Sciences
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-11-07
Description

Exclusive license agreement for development and commercialization of Nyxol across three indications. Famy funded Nyxol development through FDA approvals and undertook development in non-US markets. Received $35 million upfront payment with potential for additional milestone and royalty payments.

ir.opusgtx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in ocular gene therapy; developed and commercializes Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutations). Directly comparable as the established leader in AAV-based IRD therapeutics.

TypeDirect peer
Description

Clinical-stage gene therapy company with multiple IRD programs and proprietary AAV manufacturing capabilities. Directly comparable in target indications (IRDs) and AAV-based delivery approach.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases including wet AMD and diabetic retinopathy. Comparable as a fellow ocular gene therapy developer targeting retinal indications.

TypeDirect peer
Description

AAV gene therapy platform company with ophthalmology programs (including ABBV-RGX-314 for wet AMD in partnership with AbbVie). Comparable through shared AAV vector technology targeting retinal diseases.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for Leber Hereditary Optic Neuropathy (LHON) and IRDs. Comparable as a fellow ophthalmology-focused gene therapy developer.

TypeDirect peer
Description

Clinical-stage gene therapy company developing treatments for LCA1 and other IRDs using novel AAV capsids. Directly comparable in IRD target indications and AAV delivery platform.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on IRDs including X-linked retinitis pigmentosa. Comparable as a fellow emerging AAV gene therapy developer targeting rare retinal disorders.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company developing therapies for IRDs including Leber congenital amaurosis. Comparable in IRD focus and addressing similar genetic targets through a different modality.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing gene therapies for IRDs including RHO-adRP and modifier gene therapies. Comparable as a fellow public ophthalmology gene therapy developer.

TypeBroad incumbent
Description

Acquired by Astellas in 2023; developed Izervay for geographic atrophy. Previously sold Opus rights to two IRD gene therapy programs (BEST1 and RHO-adRP), establishing it as a relevant comparable in the ocular therapeutics and IRD gene therapy space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Opus Genetics(formerly Ocuphire Pharma)

Ophthalmic Biopharmaceuticalsopusgtx.com

Opus Genetics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases and small-molecule ophthalmic drugs, with seven gene therapy programs led by OPGx-LCA5 and partnered commercialization of approved RYZUMVI via Viatris.

What Opus Genetics(formerly Ocuphire Pharma) does

Opus Genetics, Inc. (NASDAQ: IRD; formerly Ocuphire Pharma) is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina, that develops AAV-based gene therapies for inherited retinal diseases (IRDs) and small-molecule ophthalmic therapeutics for refractive disorders and diabetic retinopathy. The company's core technology platform delivers functional genes via adeno-associated virus vectors to retinal photoreceptors or retinal pigment epithelial cells, with a pipeline of seven programs targeting LCA5, BEST1, RDH12, MERTK, RHO, CNGB1, and NMNAT1 mutations. Its lead gene therapy asset OPGx-LCA5 is in Phase 1/2 development for Leber congenital amaurosis, and OPGx-BEST1 is advancing toward the clinic for bestrophin-1-related retinal degeneration.

The company operates a hybrid business model. Nyxol (phentolamine ophthalmic solution 0.75%, branded RYZUMVI for mydriasis reversal) was FDA-approved in September 2023 and is commercialized globally by Viatris under a licensing agreement with FamyGen Life Sciences; Opus receives milestone payments and tiered double-digit royalties on worldwide net sales through 2040. APX3330, an oral Ref-1 inhibitor for diabetic retinopathy, was developed internally. The gene therapy programs are funded through a combination of dilutive equity (e.g., the $25M February 2026 Series B preferred led by Adage Capital Management) and non-dilutive strategic capital (up to $155M from Oberland Capital in April 2026, extending runway into 2029).

Opus is backed by the Foundation Fighting Blindness's RD Fund and has access to its 40-site Clinical Research Consortium and the Uni-Rare natural history study covering ~1,500 patients across over 300 IRD-associated genes. The company was formed through the November 2020 reverse merger of Ocuphire Pharma with Rexahn Pharmaceuticals, rebranded as Opus Genetics in 2023 following its strategic pivot toward AAV gene therapy, and is led by CEO George Magrath (appointed November 2023).

Opus Genetics(formerly Ocuphire Pharma) firmographics

Firmographics
Name
Opus Genetics(formerly Ocuphire Pharma)
Legal name
Opus Genetics, Inc.
Website
https://opusgtx.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Opus Genetics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases and small-molecule ophthalmic drugs, with seven gene therapy programs led by OPGx-LCA5 and partnered commercialization of approved RYZUMVI via Viatris.
Ownership category
akta.pro rank

Opus Genetics(formerly Ocuphire Pharma) industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Ophthalmic gene therapy
  • Inherited retinal diseases
  • AAV gene therapy
  • Retinal biopharmaceuticals
  • Ophthalmic pharmaceuticals

Where Opus Genetics(formerly Ocuphire Pharma) is headquartered

Location

Headquarters

HQ city
Farmington Hills
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Opus Genetics(formerly Ocuphire Pharma) business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing Royalties and Milestone Payments: Under the global license agreement with FamyGen/Viatris for Nyxol, Ocuphire receives upfront payments, development funding, regulatory milestone payments upon FDA approvals, tiered double-digit royalties on worldwide net sales through 2040, and sales milestone payments upon achievement of annual sales thresholds. Received $35 million upfront and eligible for $10 million upon RM approval.
  2. Non-Dilutive Financing: Strategic financing agreement with Oberland Capital providing up to $155 million in non-dilutive funding including $35 million upfront payment and $5 million equity investment, with potential additional funding tied to development milestones. This extends cash runway into 2029.
  3. Equity Financing: Private placement financing through sale of Series B Non-Voting Convertible Preferred Stock to institutional investors including Adage Capital Management, Trails Edge Capital Partners, and Marshall Wace, raising $25 million in gross proceeds.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Opus Genetics(formerly Ocuphire Pharma) product offering

Product offering

Core offering

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs), with seven pipeline programs targeting LCA5, BEST1, RDH12, MERTK, RHO, CNGB1, and NMNAT1 mutations. The company also advances Nyxol/RYZUMVI (phentolamine ophthalmic solution 0.75%) for mydriasis reversal, presbyopia, and night vision disturbances, plus APX3330, an oral Ref-1 inhibitor for diabetic retinopathy. Its lead programs OPGx-LCA5 and OPGx-BEST1 are advancing through clinical evaluation with FDA Rare Pediatric Disease Designation granted to OPGx-LCA5.

Product overview

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs). The company's pipeline includes seven AAV-based gene therapy programs led by OPGx-LCA5 and OPGx-BEST1, with additional candidates targeting RDH12, MERTK, RHO, CNGB1, and NMNAT1. The company also continues to advance Nyxol/Phentolamine Ophthalmic Solution (marketed as RYZUMVI for reversal of mydriasis) and APX3330 (oral Ref-1 inhibitor for diabetic retinopathy) through its partnership with Viatris and FamyGen Life Sciences. Opus Genetics was formerly known as Ocuphire Pharma and operates from Research Triangle Park, NC.

Differentiator

Problem solved

Functional benefit

Brands

  • OPGx-LCA5: AAV-based gene therapy program for LCA5-related mutations (Leber congenital amaurosis)
  • OPGx-BEST1
  • OPGx-RDH12
  • OPGx-MERTK
  • OPGx-RHO
  • Nyxol
  • RYZUMVI

Products and services

  • OPGx-LCA5 AAV8-based gene therapy candidate designed to deliver a functional LCA5 gene to retinal photoreceptors for treatment of Leber congenital amaurosis (LCA) caused by LCA5 gene mutations. One of the lead programs in Opus Genetics' seven AAV-based gene therapy pipeline, with FDA Rare Pediatric Disease Designation granted.
  • OPGx-BEST1 Gene therapy candidate for BEST1-related inherited retinal degeneration, designed to deliver a functional BEST1 gene to retinal pigment epithelial cells to produce bestrophin-1 protein and normalize photoreceptor homeostasis. Acquired from Iveric Bio in December 2022.
  • OPGx-RDH12 Preclinical gene therapy program targeting RDH12 mutations for inherited retinal diseases. Part of the company's seven AAV-based gene therapy pipeline, with clinical entry expected in 2026.
  • OPGx-MERTK Preclinical gene therapy program targeting MERTK mutations for inherited retinal diseases. Part of the company's seven AAV-based gene therapy pipeline, with clinical entry expected in 2026.
  • OPGx-RHO Gene therapy candidate acquired from Iveric Bio for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), affecting approximately one in 51,000 people in the United States.
  • OPGx-CNGB1 Preclinical AAV-based gene therapy program in the company's pipeline for inherited retinal diseases, targeting CNGB1 mutations.
  • OPGx-NMNAT1 Preclinical AAV-based gene therapy program in the company's pipeline for inherited retinal diseases, targeting NMNAT1 mutations.
  • RYZUMVI (Phentolamine Ophthalmic Solution 0.75%) FDA-approved eye drop (Phentolamine Ophthalmic Solution 0.75%) for reversal of pharmacologically-induced mydriasis. Commercialized by partner Viatris following September 2023 FDA approval. Demonstrated statistically significant superiority vs placebo in returning dilated eyes to baseline pupil diameter as early as 60 and 90 minutes.
  • Nyxol (Phentolamine Ophthalmic Solution 0.75%) Preservative-free eye drop formulation of phentolamine mesylate 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. Developed for reversal of pharmacologically-induced mydriasis (RM), presbyopia, and dim light/night vision disturbances (NVD). Licensed to Viatris for global commercialization.
  • APX3330 Oral small-molecule inhibitor of Ref-1 (reduction-oxidation effector factor-1) for treatment of diabetic retinopathy and diabetic macular edema. First-in-class drug candidate with dual mechanism of action reducing both angiogenesis (VEGF) and inflammation (NF-kB) pathways. ZETA-1 Phase 2 trial demonstrated 0% binocular 3-step worsening vs 16% for placebo (p=0.04).

Quantifiable outcome

  • OPGx-LCA5 received FDA Rare Pediatric Disease Designation, which may provide eligibility for a priority review voucher upon approval
  • +3 more outcomes

Companies that use Opus Genetics(formerly Ocuphire Pharma)

Customer profile

Segments3 records

Ideal customer profiles3 records

Opus Genetics(formerly Ocuphire Pharma) technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Opus Genetics(formerly Ocuphire Pharma) partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Iveric BiocoreStrategic or Co-development Partner · 28 December 2022Acquired rights to two preclinical-stage AAV-based gene therapy candidates for BEST1-related inherited retinal diseases and RHO-mediated autosomal dominant retinitis pigmentosa. Iveric received $500,000 upfront payment and high single-digit percentage ownership of Opus, with potential for development and regulatory milestone payments and low single-digit earnout on net sales.
  • Foundation Fighting Blindness Clinical ConsortiumcoreStrategic or Co-development Partner · 14 November 2022Global, 40-site network of clinical research centers conducting the Uni-Rare natural history study for inherited retinal diseases. Jaeb Center for Health Research serves as coordinating center.
  • Viatris Inc.coreChannel Partner/ Reseller/ Distributor · 7 November 2022Global license agreement for commercialization of Nyxol across three indications (reversal of mydriasis, presbyopia, night vision disturbances) in US, Europe, Japan, India, China and other global markets. Viatris received rights following separate transaction with FamyGen Life Sciences.
  • FamyGen Life SciencescoreOEM/ Whitelabel/ Licensing Partner · 7 November 2022Exclusive license agreement for development and commercialization of Nyxol across three indications. Famy funded Nyxol development through FDA approvals and undertook development in non-US markets. Received $35 million upfront payment with potential for additional milestone and royalty payments.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Opus Genetics(formerly Ocuphire Pharma) competitors and assessment

Company assessment

Direct peers

  • Spark Therapeutics: Pioneer in ocular gene therapy; developed and commercializes Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutations). Directly comparable as the established leader in AAV-based IRD therapeutics.
  • MeiraGTx Holdings: Clinical-stage gene therapy company with multiple IRD programs and proprietary AAV manufacturing capabilities. Directly comparable in target indications (IRDs) and AAV-based delivery approach.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases including wet AMD and diabetic retinopathy. Comparable as a fellow ocular gene therapy developer targeting retinal indications.
  • Regenxbio: AAV gene therapy platform company with ophthalmology programs (including ABBV-RGX-314 for wet AMD in partnership with AbbVie). Comparable through shared AAV vector technology targeting retinal diseases.
  • GenSight Biologics: Clinical-stage gene therapy company developing AAV-based treatments for Leber Hereditary Optic Neuropathy (LHON) and IRDs. Comparable as a fellow ophthalmology-focused gene therapy developer.
  • Atsena Therapeutics: Clinical-stage gene therapy company developing treatments for LCA1 and other IRDs using novel AAV capsids. Directly comparable in IRD target indications and AAV delivery platform.
  • Beacon Therapeutics: Clinical-stage gene therapy company focused on IRDs including X-linked retinitis pigmentosa. Comparable as a fellow emerging AAV gene therapy developer targeting rare retinal disorders.
  • ProQR Therapeutics: Clinical-stage RNA therapeutics company developing therapies for IRDs including Leber congenital amaurosis. Comparable in IRD focus and addressing similar genetic targets through a different modality.
  • Ocugen: Clinical-stage biopharmaceutical company developing gene therapies for IRDs including RHO-adRP and modifier gene therapies. Comparable as a fellow public ophthalmology gene therapy developer.

Broad incumbents

  • Iveric Bio (Astellas): Acquired by Astellas in 2023; developed Izervay for geographic atrophy. Previously sold Opus rights to two IRD gene therapy programs (BEST1 and RHO-adRP), establishing it as a relevant comparable in the ocular therapeutics and IRD gene therapy space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Opus Genetics(formerly Ocuphire Pharma) social profiles

Digital presence

Opus Genetics(formerly Ocuphire Pharma) financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Opus Genetics(formerly Ocuphire Pharma) leadership team

Management profile

Number of profiles

Profiles6 records

Opus Genetics(formerly Ocuphire Pharma) funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Opus Genetics(formerly Ocuphire Pharma) M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opus Genetics(formerly Ocuphire Pharma)

What does Opus Genetics(formerly Ocuphire Pharma) do?

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs), with seven pipeline programs targeting LCA5, BEST1, RDH12, MERTK, RHO, CNGB1, and NMNAT1 mutations. The company also advances Nyxol/RYZUMVI (phentolamine ophthalmic solution 0.75%) for mydriasis reversal, presbyopia, and night vision disturbances, plus APX3330, an oral Ref-1 inhibitor for diabetic retinopathy. Its lead programs OPGx-LCA5 and OPGx-BEST1 are advancing through clinical evaluation with FDA Rare Pediatric Disease Designation granted to OPGx-LCA5.

Is Opus Genetics(formerly Ocuphire Pharma) a public or private company?

Opus Genetics(formerly Ocuphire Pharma) is a public company. It is classified as public and is currently operating.

When was Opus Genetics(formerly Ocuphire Pharma) founded?

Opus Genetics(formerly Ocuphire Pharma) was founded in 2020. It employs 11 to 50 people.

Where is Opus Genetics(formerly Ocuphire Pharma) based?

Opus Genetics(formerly Ocuphire Pharma) is headquartered in Farmington Hills, United States, in the North America region.

How does Opus Genetics(formerly Ocuphire Pharma) make money?

Three revenue lines are on record. Licensing Royalties and Milestone Payments are the primary driver. The others are non-Dilutive Financing and equity Financing.

Who are Opus Genetics(formerly Ocuphire Pharma)'s main competitors?

Direct peers on record are Spark Therapeutics, MeiraGTx Holdings, Adverum Biotechnologies, Regenxbio, GenSight Biologics, Atsena Therapeutics, Beacon Therapeutics, ProQR Therapeutics and Ocugen. Iveric Bio (Astellas) is listed as a broad incumbent.

Does Opus Genetics(formerly Ocuphire Pharma) have an API?

No public API is recorded for Opus Genetics(formerly Ocuphire Pharma).

What industry is Opus Genetics(formerly Ocuphire Pharma) in?

Opus Genetics(formerly Ocuphire Pharma)'s product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerOpus Genetics, Inc. Doses First Participant In Phase 1/2 Clinical Trial Of OPGx-RDH12 Gene Therapy For RDH12-Associated Leber Congenital AmaurosisOpus Genetics dosed the first participant in its Phase 1/2 trial of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis. The trial follows FDA clearance of the IND and includes a $1.6 million commitment from the Global RDH12 Alliance. The therapy aims to restore RDH12 activity in retinal photoreceptors.Stock TitanOpus Genetics doses first participant in Phase 1/2 trialOpus Genetics announced the first participant was dosed in its Phase 1/2 clinical trial of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis. The trial follows FDA clearance of the IND in October 2026 and is supported by a $1.6 million commitment from the Global RDH12 Alliance.Defense WorldHC Wainwright Forecasts Strong Price Appreciation for Opus Genetics (NASDAQ:IRD) StockHC Wainwright raised its price target on Opus Genetics from $8 to $14, keeping a buy rating. The stock opened at $4.06, and the company reported a quarterly loss of $0.46 EPS, missing estimates. Analysts have an average rating of Moderate Buy with a target of $13.29.TradingViewRBC Capital maintains Opus Genetics at Outperform, raises price target to $11 from $9RBC Capital maintained Opus Genetics at Outperform and raised its price target to $11 from $9, a 22.2% increase. The target implies 160% upside from the Nov 10 close of $4.23. Recent analyst price targets range from $14 to $17.YahooOpus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue EstimatesOpus Genetics reported a Q3 loss of $0.18 per share, missing the consensus estimate of $0.14, and revenues of $1.14 million, down 43.8% from the prior year's $3.08 million. The company has surpassed consensus EPS estimates only once in four quarters.Quiver QuantitativeOpus Genetics Posts $46.5 Million Third-Quarter Net Loss | IRD Stock NewsOpus Genetics reported a third-quarter 2026 net loss of $46.5 million and license and collaborations revenue of $1.1 million. The company completed dosing in the high-dose Cohort 2 of its OPGx-BEST1 Phase 1/2 trial and expects topline data in the first quarter of 2027.Business & FinancialOpus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)Opus Genetics granted inducement options for 1,100,000 shares of its common stock, with an exercise price equal to the fair market value on the grant date. The options vest over four years, with 25% vesting on the one-year anniversary and the remaining 75% in quarterly installments, subject to acceleration or forfeiture.American Banking and Market NewsOpus Genetics (IRD) & Its Peers Financial ComparisonOpus Genetics is compared to its biotechnology peers on financial metrics, analyst ratings, and ownership. The company reports revenue of $14.20 million versus $689.45 million for rivals, and a consensus price target of $12.71 implying 246.44% upside. It beats rivals on 7 of 13 factors.Stock TitanOpus Genetics names Andrew Murphy chief scientific officerOpus Genetics appointed Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations. The appointments aim to strengthen scientific and operational capabilities as the company advances its gene therapy pipeline for inherited retinal diseases. The company's pipeline includes OPGx-BEST1, OPGx-LCA5, and OPGx-RDH12.Ticker ReportHead to Head Review: Alkermes (NASDAQ:ALKS) and Opus Genetics (NASDAQ:IRD)Alkermes beats Opus Genetics on 8 of 14 factors, including higher revenue and earnings. Opus Genetics has a stronger analyst consensus and higher upside potential, while Alkermes shows stronger profitability and institutional ownership.